They are building a state of the art manufacturing facility which is now under construction, should be ready by May or June next year and produce masss quantities of the Nicossan drug. IMO

RE: ZKEM plant:
does ZKEM have a manufacturing plant?
how does it produce its drug?
tia

It is very disturbing that they have chosen to slap us in the face like this with no pr. I say we call and call and force them to give us some news. I got into more detail at pennyhelper.com along with the phone numbers and you can see it toward the bottom of the page:

http://www.pennyhelper.com/cgi-bin/forum/Blah.pl?b-underdime/m-1152647471/s-480/

We need to harass them until they give us some information.

Hello Bill and everyone...I think I was banned from RB for some unknown reason...hmmmmm, can't figure it out. I'm long on XKEM and never had a TOS violation...oh well. Hey Bill I noticed the company is the right name but the wrong letters ZKEM on top of the page...are we in the right place?????LOL

Hello XKEM longs. I just joined ihub and thougt I'd say hello and best of luck to the true XKEM longs besides I just got booted from RB and I had no place else to go lol! I honestly believe we have a very good long term investment with XKEM and the story is just beginning to be told! I'm lookin for at least 1 or 2 PR'S in August hopefully loan news and maybe some sales projections but it might be to soon for projected sales numbers. Guess we'll see. Anyway good luck!!!!

test

Xechem International Inc, OTC BB:XKEM
Date: May 18, 2006
This stock was mentioned in all the following reports between May 10 and May 17, 2006;
1)Plunkett's Biotech & Genetics Industry Almanac
2)Reuters Investment Profile
3)Plunkett's Biotech & Genetics Industry Trends & Statistics
4)ValuEngine Summary
5)Wright Reports
6)Weiss Ratings

Seems excessive for any stock. Whats up?

Xechem Files Orphan Drug Application for HEMOXIN a Potential Treatment for Sickle Cell Disease 'SCD'

FRIDAY , MARCH 07, 2003 08:01 AM

NEW BRUNSWICK, N.J., Mar 7, 2003 (BUSINESS WIRE) -- Xechem International, Inc. (OTC BB: ZKEM) has filed its Orphan Drug Application with the United States Food and Drug Administration ("FDA") seeking Orphan Drug status for its Phyto-Pharmaceutical product, HEMOXIN(TM), which is a strong candidate as a treatment for patients suffering with Sickle Cell Disease ("SCD").

Xechem signed an exclusive worldwide license on July 18, 2002 for the manufacturing, marketing, distribution and sales of HEMOXIN(TM) (NIPRISAN(TM)) with the National Institute of Pharmaceutical Research and Development ("NIPRD"), Abuja, Government of Nigeria. The license agreement between Xechem and NIPRD is supported by patents recently issued to NIPRD in various countries including the USA. Xechem is also preparing to file an Investigational New Drug ("IND") Application for HEMOXIN(TM) with the United States Food and Drug Administration ("FDA"). To date, there has been no successful non-toxic drug developed for the treatment of SCD. HEMOXIN(TM) is a non-toxic, Phyto-Pharmaceutical medicament.

SICKLE CELL DISEASE IN THE UNITED STATES

In 1972, the 92nd US Congress passed the National Sickle Cell Anemia Control Act, which called for grant support for screening programs. In 1975, the first US State began a newborn screening program for SCD. However, there has been only one drug, Hydroxyurea (HU), which has come to the marketplace since that time, out of approximately 2,000 screened candidates with over $1 billion in research funding.

According to a study published by Allison Ashley-Koch, Quanhe Yang, and Richard S. Olney of the Centers for Disease Control and Prevention ("CDC"), SCD is a major public health concern (Ashley-Koch, A. et al, Am. J. Epidemiol 151, 839, 2000). Each year in the US, an average of 75,000 hospitalizations are due to SCD, costing approximately $475 million. The average length of per hospital visit was 6.1 days and adults tended to have longer stays than children and adolescents. SCD is also associated with significant mortality. Among children, the primary causes of mortality are bacterial infections and stroke. This genetic disorder has great impact on both the individual and society.

ORPHAN DRUG STATUS

There are two significant advantages in obtaining Orphan Drug status for HEMOXIN(TM).

The first is FDA's recognition of exclusive approval. Orphan Drug Regulations underlying the Orphan Drug Act, provide under Section 316.34 (a) FDA will send the sponsor (or, the permanent resident agent, if applicable) timely written notice recognizing exclusive approval once the marketing application for a designated orphan drug product has been approved. The written notice will inform the sponsor of the requirements for maintaining orphan drug exclusive approval for the full 7 year term of exclusive approval; and (b) When a marketing application is approved for a designated orphan drug that qualifies for exclusive approval, FDA will also publish it in the "Approved Drug Products with Therapeutic Equivalence Evaluations" information identifying the sponsor, the drug, and the date of termination of the orphan drug exclusive approval.

Given the virtual lack of commercially viable treatments for SCD in the United States, the protective aspect of a 7-year exclusive term of protection for HEMOXIN(TM) could give Xechem a significant revenue opportunity.

The second advantage is the availability of tax credits. Section 45C of the Internal Revenue Code of 1954 allows a credit against tax, up to 50 percent of certain clinical testing expenses related to the use of a drug for a rare disease or condition after it is designated as an orphan drug.

More information regarding investment tax credits under the Orphan Drug Act can be found at the following internet link: http://www.fda.gov/orphan/taxcred.htm

Xechem International, Inc., headquartered in New Brunswick, N.J., with subsidiary companies in the USA, India, Nigeria and joint venture partners in both Hong Kong and the Peoples Republic of China, is a biopharmaceutical company engaged in the research, development and production of generic and proprietary drugs from natural sources. The Company specializes in the development of niche-generic, difficult to replicate, anti-cancer, antiviral compounds, including Human Immuno-deficiency Virus ("HIV") and anti-fungal compounds. Xechem is also engaged in the research and development of several novel anti-infectives showing strong and selective efficacy against an array of antibiotic resistant bacterias, including Helicobacter pylori (H. pylori), Vancomycin resistant Enterococcus faecalis (VREF), Methicillin resistant Staphylococcus aureus (MRSA), and other antibiotic resistant Staphylococcus aureus and Candida albicans. The Company also screens extracts and pure compounds from various parts of the world for their therapeutic use.

XetaPharm (another U.S. subsidiary) develops quality controlled nutritional products such as GinkgoOnce(R), GinsengOnce(R), GarlicOnce(R), Gugulon(TM), VIDA PRAS(TM) and numerous other nutraceutical products, which are under development.

This and past press releases of Xechem International, Inc. are available at Xechem's web site at www.xechem.com.

This news release may contain certain forward-looking statements relating to Xechem's future business performance within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks, uncertainties, including the ability of the Companies to successfully develop and commercialize their technologies, and other factors that may cause the actual results, performance or achievements of the Companies to be materially different from any future results, performance or achievements of the Companies expressed or implied by such forward-looking statements.



CONTACT: Xechem International
Ramesh C. Pandey, 732/247-3300

URL: http://www.businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.



Copyright (C) 2003 Business Wire. All rights reserved.


-0-


KEYWORD: NEW JERSEY INTERNATIONAL AFRICA/MIDDLE EAST
INDUSTRY KEYWORD: MEDICAL
PHARMACEUTICAL
BIOTECHNOLOGY
GOVERNMENT
SOURCE:
Xechem
International,
Inc.


STOCK SYMBOLS: [(zkem)]

http://biz.yahoo.com/bw/030307/75079_1.html

Xechem Files Orphan Drug Application for HEMOXIN a Potential Treatment for Sickle Cell
Disease 'SCD'
Friday March 7, 8:07 am ET


NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--March 7, 2003--Xechem International, Inc.
(OTC BB: ZKEM) has filed its Orphan Drug Application with the United States Food and
Drug Administration ("FDA") seeking Orphan Drug status for its Phyto-Pharmaceutical
product, HEMOXIN(TM), which is a strong candidate as a treatment for patients suffering
with Sickle Cell Disease ("SCD").
ADVERTISEMENT


Xechem signed an exclusive worldwide license on July 18, 2002 for the manufacturing,
marketing, distribution and sales of HEMOXIN(TM) (NIPRISAN(TM)) with the National
Institute of Pharmaceutical Research and Development ("NIPRD"), Abuja, Government of
Nigeria. The license agreement between Xechem and NIPRD is supported by patents
recently issued to NIPRD in various countries including the USA. Xechem is also preparing
to file an Investigational New Drug ("IND") Application for HEMOXIN(TM) with the United
States Food and Drug Administration ("FDA"). To date, there has been no successful
non-toxic drug developed for the treatment of SCD. HEMOXIN(TM) is a non-toxic,
Phyto-Pharmaceutical medicament.

SICKLE CELL DISEASE IN THE UNITED STATES

In 1972, the 92nd US Congress passed the National Sickle Cell Anemia Control Act, which
called for grant support for screening programs. In 1975, the first US State began a
newborn screening program for SCD. However, there has been only one drug, Hydroxyurea
(HU), which has come to the marketplace since that time, out of approximately 2,000
screened candidates with over $1 billion in research funding.

According to a study published by Allison Ashley-Koch, Quanhe Yang, and Richard S. Olney
of the Centers for Disease Control and Prevention ("CDC"), SCD is a major public health
concern (Ashley-Koch, A. et al, Am. J. Epidemiol 151, 839, 2000). Each year in the US, an
average of 75,000 hospitalizations are due to SCD, costing approximately $475 million.
The average length of per hospital visit was 6.1 days and adults tended to have longer
stays than children and adolescents. SCD is also associated with significant mortality.
Among children, the primary causes of mortality are bacterial infections and stroke. This
genetic disorder has great impact on both the individual and society.

ORPHAN DRUG STATUS

There are two significant advantages in obtaining Orphan Drug status for HEMOXIN(TM).

The first is FDA's recognition of exclusive approval. Orphan Drug Regulations underlying
the Orphan Drug Act, provide under Section 316.34 (a) FDA will send the sponsor (or, the
permanent resident agent, if applicable) timely written notice recognizing exclusive approval
once the marketing application for a designated orphan drug product has been approved.
The written notice will inform the sponsor of the requirements for maintaining orphan drug
exclusive approval for the full 7 year term of exclusive approval; and (b) When a marketing
application is approved for a designated orphan drug that qualifies for exclusive approval,
FDA will also publish it in the "Approved Drug Products with Therapeutic Equivalence
Evaluations" information identifying the sponsor, the drug, and the date of termination of the
orphan drug exclusive approval.

Given the virtual lack of commercially viable treatments for SCD in the United States, the
protective aspect of a 7-year exclusive term of protection for HEMOXIN(TM) could give
Xechem a significant revenue opportunity.

The second advantage is the availability of tax credits. Section 45C of the Internal
Revenue Code of 1954 allows a credit against tax, up to 50 percent of certain clinical
testing expenses related to the use of a drug for a rare disease or condition after it is
designated as an orphan drug.

More information regarding investment tax credits under the Orphan Drug Act can be found
at the following internet link: http://www.fda.gov/orphan/taxcred.htm

Xechem International, Inc., headquartered in New Brunswick, N.J., with subsidiary
companies in the USA, India, Nigeria and joint venture partners in both Hong Kong and the
Peoples Republic of China, is a biopharmaceutical company engaged in the research,
development and production of generic and proprietary drugs from natural sources. The
Company specializes in the development of niche-generic, difficult to replicate, anti-cancer,
antiviral compounds, including Human Immuno-deficiency Virus ("HIV") and anti-fungal
compounds. Xechem is also engaged in the research and development of several novel
anti-infectives showing strong and selective efficacy against an array of antibiotic resistant
bacterias, including Helicobacter pylori (H. pylori), Vancomycin resistant Enterococcus
faecalis (VREF), Methicillin resistant Staphylococcus aureus (MRSA), and other antibiotic
resistant Staphylococcus aureus and Candida albicans. The Company also screens
extracts and pure compounds from various parts of the world for their therapeutic use.

XetaPharm (another U.S. subsidiary) develops quality controlled nutritional products such
as GinkgoOnce®, GinsengOnce®, GarlicOnce®, Gugulon(TM), VIDA PRAS(TM) and
numerous other nutraceutical products, which are under development.

This and past press releases of Xechem International, Inc. are available at Xechem's web
site at www.xechem.com.

This news release may contain certain forward-looking statements relating to Xechem's
future business performance within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended,
which are intended to be covered by safe harbors created hereby. Such forward-looking
statements involve known and unknown risks, uncertainties, including the ability of the
Companies to successfully develop and commercialize their technologies, and other factors
that may cause the actual results, performance or achievements of the Companies to be
materially different from any future results, performance or achievements of the Companies
expressed or implied by such forward-looking statements.



--------------------------------------------------------------------------------
Contact:
Xechem International
Ramesh C. Pandey, 732/247-3300



--------------------------------------------------------------------------------
Source: Xechem International, Inc.

RE: Paclitaxel
Sonus Pharmaceuticals Lead Cancer Product -- TOCOSOL Paclitaxel -- Shows Excellent Safety and Efficacy in Interim Phase 2 Clinical Study Results
Anti-Tumor Activity Demonstrated in All Studies
Wednesday September 18, 7:36 am ET


BOTHELL, Wash.--(BUSINESS WIRE)--Sept. 18, 2002-- Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS - News) today reported initial efficacy results for TOCOSOL(TM) Paclitaxel from the dose escalation stage of four Phase 2 clinical studies in non small cell lung, bladder, ovarian and colorectal cancers.
ADVERTISEMENT


The results to date demonstrate objective anti-tumor responses in all four cancers and a disease control rate ranging from 37% to 89%. Sonus will present these Phase 2 results at the RedChip(TM) Investors Conference on Thursday, September 19, in New York City. TOCOSOL Paclitaxel is a proprietary formulation of paclitaxel, the active ingredient in the leading cancer drug Taxol®.

"We have made significant progress since initiating the Phase 2 program for TOCOSOL Paclitaxel in late March of this year, and we are very excited about the preliminary results," said Michael A. Martino, President and Chief Executive Officer of Sonus Pharmaceuticals. "To date, 73 patients from the dose escalation stage of the Phase 2 studies are evaluable for efficacy, including 18 in each of the non small cell lung, bladder and colorectal studies and 19 patients in the ovarian study. I am very pleased to report that initial results demonstrate a disease control rate (partial responses plus stable disease) of 78% in non small cell lung cancer, 89% in bladder cancer, 37% in ovarian cancer and 39% in colorectal cancer.

"These efficacy results include anti-tumor activity at all of the dosing levels studied in the dose escalation stage from 80 mg/m2 to 120 mg/m2. I am pleased to report that we have completed the dose escalation stage for the Phase 2 studies, and the weekly maximum tolerated dose determined for TOCOSOL Paclitaxel is 120 mg/m2 in the non small cell lung, ovarian and colorectal studies and 100 mg/m2 in the bladder study. These weekly dose levels correspond to a range of 300 mg/m2 to 360 mg/m2 over a three-week period, which is nearly twice the approved dose of Taxol given at 175 mg/m2 once every three weeks. Even at these higher dose levels, TOCOSOL Paclitaxel has demonstrated significantly lower incidences of neuropathy and neutropenia compared to those rates described in the Taxol package insert. The Phase 2 results to date show that the level of neuropathy for TOCOSOL Paclitaxel is 75% less than Taxol, and the neutropenia level is 66% less.

"We are very encouraged by the initial Phase 2 data for TOCOSOL Paclitaxel, which continues to build upon the solid results achieved in our Phase 1 study. Our objective is to further demonstrate outstanding safety and efficacy results for TOCOSOL Paclitaxel by continuing to aggressively enroll patients in all four of the ongoing Phase 2 studies and accelerating the initiation of additional clinical studies."

Initial Phase 2 Efficacy Data:

Non Small Cell Lung Cancer:

A disease control rate of 78% was achieved in 18 evaluable patients, including 22% partial responses (tumor area reduction greater than 50%) and 56% stable disease (halting of disease progression). The majority of patients in the non small cell lung study were Stage IV, meaning they had metastatic disease, and all had failed prior chemotherapy.

Bladder Cancer:

An 89% disease control rate has been demonstrated in 18 evaluable patients, which includes 17% partial responses and 72% stable disease. All patients with bladder cancer had locally advanced, recurrent or metastatic disease, and had failed prior platinum treatment. None of the bladder cancer patients have had disease progression while being treated with TOCOSOL Paclitaxel.

Ovarian Cancer:

The disease control rate in 19 evaluable patients was 37% (16% partial responses, 21% stable disease). All patients were platinum refractory/resistant, meaning that they progressed while on or within six months of therapy with a platinum agent. These patients were also in the later stage of disease, Stage III or IV. These types of ovarian cancer patients are the most difficult to treat.

Colorectal Cancer:

The disease control rate in 18 evaluable patients was 39%, including 6% partial responses and a stable disease rate of 33%. All patients in the colorectal study were in the advanced stages of disease.

About TOCOSOL Paclitaxel

Formulated with Sonus' proprietary TOCOSOL drug delivery technology, TOCOSOL Paclitaxel may provide administration benefits, reduced side effects and better efficacy. The Phase 1 clinical study for TOCOSOL Paclitaxel was completed in May 2002. Encouraging Phase 1 results indicated that TOCOSOL Paclitaxel can be administered in 15 minutes or less compared to the three-hour infusion required with Taxol. Phase 1 results also demonstrated disease control in 15 out of 36 patients (42%).

About Sonus Pharmaceuticals, Inc.

Located near Seattle, Washington, Sonus Pharmaceuticals is applying its expertise in drug delivery to make therapeutic drugs safer, easier to administer and more effective. In addition to TOCOSOL Paclitaxel, the Company is developing a number of other potential product candidates incorporating the TOCOSOL technology in applications to treat cancer, cardiovascular disease, diabetes and infection. Sonus news releases and other corporate information are available on the Company's web site at www.sonuspharma.com.

Certain of the statements made in this press release are forward-looking such as those, among others, relating to the development of drug delivery products and potential applications for these products. As discussed in the Sonus Pharmaceuticals Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 5, 2002, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: the Company's products will require extensive clinical testing and approval by regulatory authorities; such approvals are lengthy and expensive and may never occur, and may be subject to certain other regulatory requirements; there can be no assurance that Sonus will be successful in its efforts to develop drug delivery products; there can be no assurance that Phase 1 and Phase 2 studies with TOCOSOL Paclitaxel will be successful or that increased efficacy will result from Sonus' emulsion-based formulations; the Company's results from operations have varied and will continue to vary from quarter to quarter and will depend upon, among other factors, timing and cost of clinical trials planned by Sonus and receipt of collaborative partner payments, if any; there can be no assurance that the Company will receive any future collaborative partner payments or that its cash requirements will be met by any such payments; and Sonus may seek external financing through available means, which may include debt and/or equity financing or the licensing or sale of proprietary or marketing rights, and there can be no assurance that financing will be available on acceptable terms, if at all.

Taxol(TM) is a registered trademark of Bristol-Myers Squibb Company.



--------------------------------------------------------------------------------
Contact:
Sonus Pharmaceuticals
Pamela L. Dull, 425/487-9500



--------------------------------------------------------------------------------
Source: Sonus Pharmaceuticals

ZKEM, news
NEW BRUNSWICK, N.J., Aug 1, 2002 (BUSINESS WIRE) -- Xechem International, Inc. (ZKEM, Trade) announced that it has acquired the exclusive world-wide rights to an important innovative drug product for treating and managing the genetic and debilitating sickle cell anemia disease.

The exclusive rights to this product have been acquired from the National Institute for Pharmaceutical Research and Developments (NIPRD), Federal Republic of Nigeria, which has forty-six patents worldwide covering this new drug, and which is currently in phase III clinical trials in Nigeria.

Currently, there does not exist an FDA approved (or equivalent regulatory approved) drug for managing sickle cell anemia, for which no pharmaceutical cure exists. Xechem's revolutionary new product, for which regulatory approval will be sought worldwide and expedited approval sought in the United States under the Orphan Drug Act, actually manages the disease in protecting red blood cells against cycling, and acts in reversing cycled red blood cells.

Xechem's involvement with its long history of pharmaceutical development and expertise has sparked much interest and anticipation in bringing this desperately needed drug product to market, with Xechem even receiving e-mails from parents of children afflicted with this disease.

As stated by Professor A. B. C. Nwosu, the Honorable Minister of Health, Federal Ministry of Health, the Federal Republic of Nigeria, "It is my great pleasure and indeed the pride of my Ministry that I am here this afternoon to sign the NIPRD-Xechem Agreement on our new phytomedicine (NIPRISAN) for the management of sickle cell disease, which affects a significant percentage of the black population throughout the world. With today's signing, NIPRD will formally transfer its technology on NIPRISAN to Xechem for the manufacture of this drug in Nigeria and its marketing and distribution all over the world. This arrangement will guarantee the availability of this product in the international market for the benefit of those in need worldwide. It is thought that Xechem will be able to put this important new drug on the market within the next six months. I sincerely commend the pioneering role and effort of Xechem in venturing outside of the American Continent into Africa and I assure you that Xechem's investment in the Nigerian market will not be regretted."

According to Xechem's President and CEO, Dr. Ramesh C. Pandey, "We at Xechem feel honored to be able to make this important new drug product available to the millions of people around the world, who in the past have had simply no way of managing this genetic sickle cell anemia disease. We hope to begin distributing this product throughout the African continent within the year and throughout the World within the next year."

Xechem International, Inc., headquartered in New Brunswick, NJ, with subsidiary companies in the USA, India, Nigeria and joint venture partners in both Hong Kong and the People's Republic of China, is a biopharmaceutical company of which Xechem, Inc. (a US subsidiary) is engaged in the research, development and production of generic and proprietary drugs from natural sources, specializing in the development of niche-generic, difficult to replicate anticancer, antiviral, including Human Immuno-deficiency Virus (HIV) and antifungal compounds. Xechem is also engaged in the research and development of several novel anti-infectives showing strong and selective efficacy against an array of antibiotic resistant bacterias, including Helicobacter pylori (H. pylori), Vancomycin resistant Enterococcus faecalis (VREF), Methicillin resistant Staphylococcus aureus (MRSA), and other antibiotic resistant Staphylococcus aureus and Candida albicans. The Company also screens extracts and pure compounds from various parts of the world for their therapeutic use.

XetaPharm (another U.S. subsidiary) develops quality controlled nutritional products such as GinkgoOnce(R), GinsengOnce(R), GarlicOnce(R), Gugulon(TM), VIDA PRAS(TM) and numerous other nutraceutical products, which are under development.

This and past press releases of Xechem International, Inc. are available at Xechem's web site at www.xechem.com.

For further information, contact John P. Luther, Esq., Vice President & General Counsel, at (732) 247-3300.

This news release may contain certain forward-looking statements relating to Xechem's future business performance within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks, uncertainties, including the ability of the Companies to successfully develop and commercialize their technologies, and other factors that may cause the actual results, performance or achievements of the Companies to be materially different from any future results, performance or achievements of the Companies expressed or implied by such forward-looking statements.


CONTACT: Xechem International, Inc., New Brunswick
John P. Luther, 732/247-3300
URL: http://www.businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2002 Business Wire. All rights reserved.

POSTED FROM RB........

http://ragingbull.lycos.com/mboard/boards.cgi?board=ZKEM&read=15552

News Flash: Pharmaceutical and Nutraceutical Company
Making Waves with Cancer Drug Compounds
-- ZKEM Receives $1.15 Mil. in Additional Funding
Stock Still Trades at 0.8 cents/share!!

Many of Today's Most Widely Prescribed Drugs Rely on Compounds Found in Nature. ZKEM Isolates Those Compounds and Aims at Bringing Them to Market. ZKEM's Stock is Priced at 0.8 Cents - A Mere 3.2 Cent Increase in Stock Price Would Produce a 400% Return on Investment!

Today's profiled company, Xechem International, Inc. (OTCBB: ZKEM) is trading at only 0.8 cents/share. We ask: Which is easier - for a 0.8 cent stock to go to 8 cents or an $8 stock to explode tenfold to $80?

This is exactly why percentage changes with these types of <1 cent stocks can sometimes be phenomenal. If you bought one million shares of ZKEM at its current price and the stock moved up to just 4 cents a share, your $8,000 investment would grow to $40,000, representing a 400% gross profit!

Can ZKEM move to 4 cents, or even $4 a share in the long run? Maybe. The company's business model is very interesting and investors are starting to pay attention. In fact, ZKEM announced yesterday that it has received over $1.1 million in additional funding to further accelerate its development programs.

Accredited investors don't just invest $1.1 million without researching the company and its industry very thoroughly. That's why ZKEM's recent round of funding demonstrates that its investors must believe in the company's future. This is great news to all ZKEM investors!

Company:

ZKEM is a fully integrated pharmaceutical and nutraceutical company, providing generic and proprietary drugs for tomorrow's marketplace. The company is engaged in the research, development and production of generic and proprietary drugs from natural sources. It specializes in the development of niche-generic, difficult to replicate anticancer, antiviral (including Human Immunodeficiency Virus, HIV) and anti-fungal compounds.

ZKEM also screens extracts and pure compounds from various parts of the world, including China, India and Nigeria for their therapeutic use.

Plants and herbs have long been recognized and used for their therapeutic benefit. As a matter of fact, the World Health Organization (WHO) estimates that nearly 80% of the world's population relies on "Traditional Herbal Remedies" as a primary source of health care.

Approximately one fourth of all prescription drugs used in the U.S. alone contain pure compounds based upon molecules originally isolated from plants. The quest to discover these compounds in a variety of medicinal plants, marine sources and fermentation processes is one of ZKEM's top priorities.

Today's News

(BSNS WIRE) Xechem Announces Issuance of a New Australian Patent for Second
Xechem Announces Issuance of a New Australian Patent for Second Generation
Paclitaxel Analogs


Business/Health Editors

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Feb. 27, 2001--Xechem
International, Inc. (OTC BB: ZKEM) today announced that the
Commissioner of Patents, Commonwealth of Australia Patent Office,
granted a second Australian Patent, Patent No. 724929, on January
25th, 2001 to Xechem for its paclitaxel analogs, preparation and use
as antitumor agents.
According to Xechem's President & CEO, Dr. Ramesh Pandey, "We are
very pleased to receive the second Australian patent on the paclitaxel
analogs (also called second generation paclitaxel). This is another
example of Xechem's commitment to protect its intellectual property in
its growing portfolio of the innovative paclitaxel analogs. We still
have over 30 patents pending in this area, as we proceed further into
the year 2001 and beyond, we expect many more U.S. and international
patents to be issued."

Xechem International, Inc., headquartered in New Brunswick, NJ,
with subsidiary companies in USA, India and joint venture partners in
both Hong Kong and Peoples Republic of China, is a biopharmaceutical
company of which Xechem, Inc. (a US subsidiary) is engaged in the
research, development and production of generic and proprietary drugs
from natural sources, specializing in the development of
niche-generic, difficult to replicate anticancer, antiviral (including
Human Immuno-deficiency Virus, HIV) and antifungal compounds. The
Company also screens extracts and pure compounds from China and India
for their therapeutic use. (See press release of February 14, 2001)
XetaPharm(TM)(another U.S. subsidiary) develops quality controlled
nutritional products such as GinkgoOnce(R), GinsengOnce(R),
GarlicOnce(R), Gugulon(TM), and Co-Enzyme Q-10 and numerous products
that are under development. (www.xetapharm.com)
This and past press releases of Xechem International, Inc. are
available at Xechem's web site at www.xechem.com.
For further information, contact the President and Chief Executive
Officer, Dr. Ramesh C. Pandey at (732) 247 - 3300.

This news release may contain certain forward-looking statements
relating to Xechem's future business performance within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended, which are intended
to be covered by safe harbors created hereby. Such forward-looking
statements involve known and unknown risks, uncertainties, including
the ability of the Companies to successfully develop and commercialize
their technologies, and other factors that may cause the actual
results, performance or achievements of the Companies to be materially
different from any future results, performance or achievements of the
Companies expressed or implied by such forward-looking statements.

--30--jeh/ny* csm

CONTACT: Xechem International, New Brunswick
Dr. Ramesh C. Pandey, 732/247-3300

KEYWORD: NEW JERSEY
INDUSTRY KEYWORD: BIOTECHNOLOGY LEGAL/LAW MEDICAL PHARMACEUTICAL
PRODUCT

Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: http://www.businesswire.com

Well Varok, JC and gang I hope this is blast-off. We need another move into the teens.

Willy

Wednesday February 7, 10:08 am Eastern Time
Press Release
Xechem Announces Issuance of a Broad U.S. Patent No. 6,177,456 For New Second Generation Paclitaxel
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Feb. 7, 2001--Xechem International, Inc. (OTC BB ZKEM) today announced that the U.S. Patent & Trademark Office has issued US Patent No. 6,177,456, January 23, 2001 containing broad claims to novel second generation paclitaxel analogs developed at Xechem's New Brunswick Laboratories.

Preliminary studies show antineoplastic efficacy of the new, novel analogs against a wide array of cancer tumor cells.

The new second generation paclitaxel analog patent covers several compounds, pharmaceutical formulations comprising the compounds, a method for administering such compounds for treating both animal and human tumors, and methods for production of the compounds.

According to Xechem's President & CEO, Dr. Ramesh Pandey, ``We are excited about the issuance of the new U.S. Patents for Xechem's growing portfolio of promising and innovative new paclitaxel analogs and paclitaxel formulations which are strategically poised to become a major presence in this important industry. With the exclusivity afforded by the various issued patents for second generation paclitaxel, we hope to develop unique new products of choice in this important and burgeoning area for patients in need of alternatives to conventional chemotherapy treatment. With the recent FDA approval of generic entry into the paclitaxel market, Xechem is also working on an Abbreviated New Drug Application (ANDA) for generic paclitaxel for submission to the US FDA in the next few months.''

Xechem International of New Brunswick, NJ, with subsidiary companies in USA, India and joint venture partners in both Hong Kong and Peoples Republic of China, is a biopharmaceutical company of which Xechem, Inc. (a US subsidiary) is engaged in the research, development and production of generic and proprietary pharmaceuticals from natural sources, specializing in the development of niche, generic, difficult to replicate anticancer, antiviral (including Human Immuno-deficiency Virus, HIV) and antifungal compounds. The Company also screens extracts and pure compounds from China and India for their therapeutic use.

XetaPharm (another U.S. subsidiary) develops quality controlled nutritional products as GinkgoOnce®, GinsengOnce®, GarlicOnce®, Gugulon(TM), and Co-Enzyme Q-10 and numerous products, which are under development. (www.xetapharm.com)

This and past press releases of Xechem International, Inc. are available at Xechem's web site at www.xechem.com.

This news release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks, uncertainties, including the ability of the Companies to successfully develop and commercialize their technologies, and other factors that may cause the actual results, performance or achievements of the Companies to be materially different from any future results, performance or achievements of the Companies expressed or implied by such forward-looking statements.


--------------------------------------------------------------------------------
Contact:

Xechem International, New Brunswick
Dr. Ramesh C. Pandey
President and Chief Executive Officer
732/247-3300

NEWS


Xechem International, Inc. Retains Grant Thornton LLP as Its Auditors

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Jan. 31, 2001--Xechem International, Inc. (OTCBB:ZKEM) is pleased to announce that it has retained the services of the accounting firm of Grant Thornton LLP to perform financial audits of Xechem International, Inc. and its subsidiaries.

Dr. Ramesh C. Pandey, President & CEO stated that ``Grant Thornton was retained as auditors for Xechem due primarily to the continuing expansion of the Company into the international arena, mainly Asia. The Company feels that Grant Thornton's international expertise will be of great benefit to the Company now and in the future. The Company also plans to take the benefit of Grant Thornton's numerous other services (consulting, financial planning etc.) and make them a valued asset in our continuing growth and long range goals.''

Xechem International, Inc., headquartered in New Brunswick, NJ, with subsidiary companies in USA, India and joint venture partners in both Hong Kong and Peoples Republic of China, is a biopharmaceutical company of which Xechem, Inc. (a US subsidiary) is engaged in the research, development and production of generic and proprietary drugs from natural sources, specializing in the development of niche-generic, difficult to replicate anticancer, antiviral (including Human Immuno-deficiency Virus, HIV), antifungal and anti-infective compounds. The Company also screens extracts and pure compounds from China and India for their therapeutic use. XetaPharm, Inc., a subsidiary of Xechem develops high quality controlled nutraceutical products such as - GinkgoOnce®, GarlicOnce®, GinsengOnce®, Gugulon(TM) and Co-Q10 as well as numerous products that are under development.

This news release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks, uncertainties, including the ability of the Companies to successfully develop and commercialize their technologies, and other factors that may cause the actual results, performance or achievements of the Companies to be materially different from any future results, performance or achievements of the Companies expressed or implied by such forward-looking statements.


--------------------------------------------------------------------------------
Xechem International, Inc., New Brunswick
Dr. Ramesh C. Pandey, 732/247-3300
News provided by www.nando.net

NEWS


Xechem International, Inc. Retains Grant Thornton LLP as Its Auditors

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Jan. 31, 2001--Xechem International, Inc. (OTCBB:ZKEM) is pleased to announce that it has retained the services of the accounting firm of Grant Thornton LLP to perform financial audits of Xechem International, Inc. and its subsidiaries.

Dr. Ramesh C. Pandey, President & CEO stated that ``Grant Thornton was retained as auditors for Xechem due primarily to the continuing expansion of the Company into the international arena, mainly Asia. The Company feels that Grant Thornton's international expertise will be of great benefit to the Company now and in the future. The Company also plans to take the benefit of Grant Thornton's numerous other services (consulting, financial planning etc.) and make them a valued asset in our continuing growth and long range goals.''

Xechem International, Inc., headquartered in New Brunswick, NJ, with subsidiary companies in USA, India and joint venture partners in both Hong Kong and Peoples Republic of China, is a biopharmaceutical company of which Xechem, Inc. (a US subsidiary) is engaged in the research, development and production of generic and proprietary drugs from natural sources, specializing in the development of niche-generic, difficult to replicate anticancer, antiviral (including Human Immuno-deficiency Virus, HIV), antifungal and anti-infective compounds. The Company also screens extracts and pure compounds from China and India for their therapeutic use. XetaPharm, Inc., a subsidiary of Xechem develops high quality controlled nutraceutical products such as - GinkgoOnce®, GarlicOnce®, GinsengOnce®, Gugulon(TM) and Co-Q10 as well as numerous products that are under development.

This news release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks, uncertainties, including the ability of the Companies to successfully develop and commercialize their technologies, and other factors that may cause the actual results, performance or achievements of the Companies to be materially different from any future results, performance or achievements of the Companies expressed or implied by such forward-looking statements.


--------------------------------------------------------------------------------
Xechem International, Inc., New Brunswick
Dr. Ramesh C. Pandey, 732/247-3300
News provided by www.nando.net

Jenny I sent you a private message,just curious if you got it.I am new to this process.They have a Fonx board here.You can also catch me on CNBC board as well.Later

OT: Varok, I am "DupliCat" over at RB. I know you on another board (besides ZKEM) too, don't I? Is it FONX? If it is you should start a FONX board here at Invester's Forum. The RB Board is such a clique and there is far too much personal banter --- is impossible to read that board.

Welcome Jenny and Happy New Year..

Thanks for the Board, Varok!

Happy Investing, everyone!

Jenny

Matt,no problem....Welcome aboard.

Varok,

Welcome aboard!

Edited the title to the actual company name....that ok?

Enjoy,

FM

Welcome all members of the ZKEM stockholders club......